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Abstract: The study evaluated the potential of nanoemulsions for the topical delivery of 
  5-aminolevulinic acid (ALA) and methyl ALA (mALA). The drugs were incorporated in 
  oil-in-water (O/W) and water-in-oil (W/O) formulations obtained by using soybean oil or 
squalene as the oil phase. The droplet size, zeta potential, and environmental polarity of the 
nanocarriers were assessed as physicochemical properties. The O/W and W/O emulsions 
showed diameters of 216–256 and 18–125 nm, which, respectively, were within the range of 
submicron- and nano-sized dispersions. In vitro diffusion experiments using Franz-type cells 
and porcine skin were performed. Nude mice were used, and skin fluorescence derived from 
protoporphyrin IX was documented by confocal laser scanning microscopy (CLSM). The load-
ing of ALA or mALA into the emulsions resulted in slower release across cellulose membranes. 
The release rate and skin flux of topical drug application were adjusted by changing the type of 
nanocarrier, the soybean oil O/W systems showing the highest skin permeation. This formulation 
increased ALA flux via porcine skin to 180 nmol/cm2/h, which was 2.6-fold that of the aque-
ous control. The CLSM results showed that soybean oil systems promoted mALA permeation 
to deeper layers of the skin from ∼100 µm to ∼140 µm, which would be beneficial for treating 
subepidermal and subcutaneous lesions. Drug permeation from W/O systems did not surpass 
that from the aqueous solution. An in vivo dermal irritation test indicated that the emulsions 
were safe for topical administration of ALA and mALA.
Keywords: nanoemulsions, 5-aminolevulinic acid, methyl 5-aminolevulinic acid, skin perme-
ation, soybean oil, squalene
Introduction
Non-melanoma skin cancers, which include basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC), represent the most common malignant neoplasms 
in humans.1 Topical application of 5-aminolevulinic acid (ALA) as a precursor for the 
photosensitizer, protoporphyrin (Pp) IX, is used in photodynamic therapy (PDT) for 
treating BCC and SCC.2 ALA generates endogenous porphyrins via the heme cycle. 
Subsequent irradiation of PDT leads to singlet oxygen production and free radicals, 
causing cellular damage and tissue necrosis.3 ALA-PDT is useful for treating skin 
cancers, actinic keratoses, psoriasis, and acne.4 Approaches were taken to increase 
the cellular uptake by increasing the diffusion of ALA across plasma membranes by 
using more-lipophilic ALA prodrugs such as methyl ALA (mALA).5 mALA also 
shows less of an inflammatory response in skin compared with its parent form.6 
Because ALA is a polar compound, the permeability via the skin is low, making it 
difficult to reach targets in skin tissues. PDT of neoplastic lesions generally uses high International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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ALA loadings of 20% (w/w).7 Between 60% and 80% of 
patients in clinical trials experience treatment-related local 
phototoxicity. Several attempts were made to increase the 
skin flux of ALA to reduce the dose, such as iontophoresis, 
permeation enhancers, and patches.8 Many carriers are also 
used to deliver ALA including liposomes, emulsions, and a 
nanocolloid lotion.9
Liposomes have come into focus as a valuable   delivery 
system for ALA.10 However, a great disadvantage in using 
entrapped ALA is the low incorporation efficiency in 
  liposomes.11 Moreover, the costs associated with   liposomes 
and their inherent instability may limit their utility. Lipid 
nano/submicron emulsions are another choice for drug 
  delivery via the skin. Nanoemulsions are a class of emul-
sions with a droplet size of 20–200 nm.12 They do not 
  spontaneously form, and their properties depend on the 
thermodynamic conditions and preparation methods. Nano/
submicron emulsions are well accepted for their ability to 
increase skin permeation, prolong action on the skin, and 
protect the drug from instability.13,14
Oil-in-water (O/W) and water-in-oil (W/O) emulsions 
are used in clinical studies, all with therapeutic success in 
dermatology. The primary aim of this study was to develop 
and evaluate O/W and W/O nanoemulsions to increase the 
absorption of ALA and mALA. Our secondary aim was to 
elucidate the influence of oil components on drug delivery 
by the nanocarriers. Soybean oil and squalene were used as 
the different oils for comparison. The permeation enhancer, 
α-terpineol, was also loaded in the systems. In this report, 
we describe the physicochemical characterization of the 
emulsions and the results of in vitro and in vivo studies 
on the skin permeation of ALA and its prodrug. The skin 
  irritant response to the emulsions was assessed using in vivo 
methods, including transepidermal water loss (TEWL) and 
colorimetry.
Experimental
Materials
ALA, mALA, soybean oil, squalene, Pluronic F68 (PF68), 
α-terpineol, Span 80, and Nile red were purchased from 
Sigma-Aldrich Chemical (St. Louis, MO, USA). Myverol 
18-04K (palmitinic acid monoglyceride) was supplied by 
Quest (Naarden, the Netherlands). Brij 98 was obtained 
from Acros Organics (Geel, Belgium). Cellulose   membranes 
  (Cellu-Sep® T2, with a molecular weight cutoff of 
6000–8000) were provided by Membrane Filtration Products 
(Seguin, TX, USA).
Preparation of O/W emulsions
Lipid emulsions were prepared using hot, high-pressure 
homogenization and ultrasonication techniques. The oil 
and aqueous phases were prepared separately. The oil 
phase   consisted of 12% (w/v) soybean oil or squalene and 
0.3% Myverol as the lipophilic emulsifier, while the   aqueous 
phase consisted of double-distilled water (DDW) and a 
  hydrophilic emulsifier (2.5% PF68). ALA or mALA (38 mM) 
used as the incorporated drug was positioned in the aqueous 
phase if necessary. Both phases were separately heated to 
55°C for 15 min. The aqueous phase was added to the oil phase 
and mixed for 5 min at 55°C. The mixture was homogenized 
in a high-shear homogenizer (Pro 250, Pro Scientific, Monroe, 
CT, USA) at 12,000 rpm for 10 minutes. The mixture was 
further treated using a probe-type   sonicator (VCX600, Sonics 
and Materials, Newtown, CT, USA) for 10 minutes at 35 W. 
The total volume of the resulting product was 10 mL.
Preparation of W/O emulsions
The oil phase consisted of soybean oil or squalene (44%) and 
Span 80 (30%), while the aqueous phase consisted of water 
(10%), Brij 98 (16%), and the drug. The two phases were 
separately heated to 55°C. The oil phase was further mixed 
using a high-shear homogenizer (Pro 250) for 20 minutes. 
Then the oil phase was added to the aqueous phase and soni-
cated using a probe-type sonicator (VCX600) for 10 minutes 
at 35 W. The total volume of the final product was 10 mL.
Determination of the size and zeta 
potential
The mean droplet size (z-average) and zeta potential of 
the nanoemulsions were measured by photon correlation 
spectroscopy (Malvern Nano ZS® 90, Malvern Instruments, 
Worcestershire, UK) using a helium-neon laser with a 
wavelength of 633 nm. Photon correlations of   spectroscopic 
measurements were carried out at a scattering angle of 90°. 
The O/W emulsions were diluted 1:100 with water before 
the measurement. In the case of W/O emulsions, the 
formulations were diluted 5-fold with soybean oil or squalene 
for detection.
Encapsulation efficiency of drugs  
in the emulsions
The encapsulation efficiency of ALA and mALA entrapped in 
the O/W emulsions was determined by an ultracentrifugation 
method. The product was centrifuged at 48,000 × g and 4°C International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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for 30 minutes in a Beckman Optima MAX® ultracentrifuge 
(Beckman Coulter, Fullerton, CA, USA) in order to separate 
the incorporated drug from the free form. The supernatant 
and precipitate were analyzed by high-performance liquid 
chromatography (HPLC) to determine the encapsulation 
percentage (%) of the total drug load. The HPLC method for 
ALA and mALA was described previously.15
Molecular environment of the emulsions
The lipophilic fluorescent marker, Nile red, was used as 
the model solute, and the molecular environment   (polarity) 
was determined by fluorometric spectrophotometry based 
on the solvatochromism of Nile red. O/W emulsions 
with 1 ppm Nile red were prepared as described above. 
  Emission fluorescence spectra were determined with a 
Hitachi F-2500 spectrometer (Tokyo, Japan). The spectra 
of   emulsions with Nile red were recorded with both slit 
widths set to 10 nm. The λex was fixed at 546 nm, and the 
emission spectra were recorded from 570 to 700 nm at a 
scanning speed of 300 nm/min.
Animals
The animal experimental protocol was reviewed and 
approved by the Institutional Animal Care and Use Commit-
tee of Chang Gung University. The committee confirmed that 
the animal experiment followed the guidelines as set forth 
by the Guide for Laboratory Factlines and Care. Female nude 
mice (ICR-Foxn1nu strain) aged 8 weeks were obtained from 
the National Laboratory Animal Center (Taipei, Taiwan). 
Pathogen-free pigs (1 week old) were supplied by the Animal 
Technology Institute Taiwan (Miaoli, Taiwan).
In vitro skin permeation
The skin permeation of ALA and mALA was measured using 
a Franz cell assembly. Full-thickness dorsal skin of a pig 
was mounted between the donor and receptor compartments. 
A cellulose membrane instead of porcine skin was also used 
as a barrier to examine drug permeation. The donor consisted 
of 0.5 mL of vehicle containing drugs. The receptor medium 
(5.5 mL) was pH 7.4 citrate-phosphate buffer. The available 
diffusion area between compartments was 0.785 cm2. The 
stirring rate and temperature of the receptor were respectively 
maintained at 600 rpm and 37°C. At appropriate intervals, 
300-µL aliquots of the receptor medium were withdrawn and 
immediately replaced with equal volumes of fresh buffer. The 
cumulative amounts of ALA and mALA were determined 
by HPLC.
In vivo skin permeation examined 
through confocal laser scanning 
microscopy (cLsM)
Localization of ALA and mALA within nude mouse skin was 
determined by CLSM after in vivo topical administration. 
A glass cylinder with an available area of 0.785 cm2 was 
attached to the back skin of a nude mouse with glue. ALA 
or mALA in the vehicles at a concentration of 38 mM was 
added to the cylinder. The application times of the vehicle 
were 2, 4, and 8 hours. After excising the skin onto which the 
vehicle was applied, the skin surface was washed 10 times 
with a cotton cloth immersed in methanol. The skin samples 
obtained were examined for PpIX fluorescence images by 
CLSM. The skin thickness was optically scanned at about 
10-µm increments through the Z-axis of a Leica TCS SP2 
confocal microscope (Wetzlar, Germany). Optical excitation 
was carried out with a 488-nm argon laser beam, and the 
fluorescence emission was detected at 590 nm.
In vivo skin irritation test
A 0.6-mL aliquot of the nanoemulsions was uniformly spread 
over a sheet of non-woven polyethylene cloth (1.5 × 1.5 cm), 
which was then applied to the back area of a nude mouse. 
The polyethylene cloth was fixed with Tegaderm® adhesive 
dressing (3M, USA) and Fixomull® stretch adhesive tape 
(Beiersdorf AG, Germany). After 24 hours, the cloth was 
removed, and the treated skin area was swabbed clean 
with a cotton wool swab. Thirty minutes after withdrawing 
the vehicle, TEWL, colorimetric parameters, and the pH 
of the applied skin were measured. TEWL was recorded 
using a   Tewameter® (TM300, Courage and Khazaka, Köln, 
  Germany). Measurements taken at a stable level were 
  performed 30 s after application of the TEWL probe to the 
skin. TEWL was automatically calculated and expressed in 
g/m2/h. A spectrocolorimeter (CD100, Yokogawa Electrical, 
Tokyo, Japan) was used to measure the skin erythema (a*). 
The skin surface pH was determined using a Skin-pH-Meter® 
PH 905 (Courage and Khazaka, Germany). An adjacent 
untreated site was used as a baseline standard for each 
determination. The temperature and relative humidity in the 
laboratory were respectively maintained at 26°C and 55%.
statistical analysis
A statistical analysis of differences between different treat-
ments was performed using unpaired t test. A 0.05 level of 
probability was taken as the level of significance. An analysis 
of variance (ANOVA) test was also used if necessary.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Results
Determination of the size and zeta 
potential
Both O/W and W/O emulsions were prepared as nanocar-
riers for ALA and its prodrug. The average diameter and 
zeta potential of the resulting products without drugs were 
first determined and are presented in Table 1. The droplet 
size of O/W emulsions ranged 216∼256 nm. The size 
analysis showed a mean diameter of 256 nm for soybean 
oil-loaded emulsions (W1). Replacement of the soybean 
oil by squalene (W2) led to a reduction in the size from 256 
to 238 nm (P , 0.05). The addition of α-terpineol (4%) to 
the soybean oil emulsions produced systems (W3) with a 
smaller size of 216 nm (P , 0.05). Contrary to the results 
of the O/W   emulsions, the size of the squalene systems (O2) 
was significantly larger (P , 0.05) than that of soybean 
oil-prepared ones (O1) in W/O emulsions. As depicted in 
Table 1, zeta potentials of most systems were negative. 
O/W emulsions with soybean oil (W1) exhibited a surface 
charge of -20 mV , which was   significantly lower (P , 0.05) 
than that of   emulsions containing squalene (-25 mV , W2). 
The addition of α-terpineol (W3) did not affect the zeta 
potential (P . 0.05). The absolute zeta potential of W/O 
emulsions was approximately zero, with restricted   negative 
charges at the interface of the soybean oil and squalene 
systems (O1 and O2).
After loading ALA within the developed O/W   systems, 
the mean droplet size did not significantly increase 
(P . 0.05) as shown in Table 2. However, with mALA, the 
size significantly increased (P , 0.05) after it was loaded into 
O/W emulsions. The incorporation of ALA or mALA into 
drug-free W/O emulsions resulted in a significant increase 
in the average size (P , 0.05). The loading of ALA showed 
a more-prominent increase in size compared to mALA in 
W/O carriers.
Encapsulation efficiency of drugs in the 
emulsions
The entrapment of ALA and mALA in the inner phase 
of O/W emulsions was examined, and results are given 
in Table 3. Drug encapsulation in W/O systems was not 
detected, since no phase separation was observed after 
ultracentrifugation. Nevertheless, it is believed that most of 
the ALA and mALA molecules resided in the inner phase 
of W/O   systems because of their high solubility in water. 
As shown in Table 3, a greater amount of mALA was 
incorporated in oil droplets compared with ALA (P , 0.05). 
More than half of the loaded amount of mALA was entrapped 
in the oil phase. Drugs could partition into soybean oil more 
easily than into squalene (P , 0.05). The incorporation 
of α-terpineol resulted in a slight but significant decrease 
(P , 0.05) in drug encapsulation.
Molecular environment of the emulsions
The absorption bands of Nile red varied in shape,   position, 
and intensity with the nature of the environment. The 
  emission maximum of Nile red was near 600 nm. The emis-
sion spectra of Nile red in O/W emulsions are shown in 
Figure 1. The fluorescence is quenched in aqueous media 
and more-hydrophilic environments.16 The results indicated 
an increasing trend of hydrophilicity of W2 . W1 . W3. 
Squalene created a more-hydrophilic inner phase for 
emulsions compared to soybean oil. α-Terpineol incorpora-
tion enhanced the lipophilicity of the systems.
In vitro skin permeation
The skin permeation of ALA and mALA was evaluated 
using Franz diffusion cells. Figure 2 shows the permeation 
kinetics of ALA (Figure 2A) and mALA (Figure 2B) from 
O/W dispersions. The control vehicle for both drugs was 
DDW. The cumulative amounts of drugs at different times 
in the receptor are shown, and the fluxes (nmol/cm2/h) 
  calculated from the slopes are summarized in Table 4. The 
drug that   permeates across the skin in an in vitro status 
dictates the amount available for subcutaneous or deeper 
skin tissues and   systematic circulation. For the control group, 
the fluxes of ALA and mALA were 70 and 43 nmol/cm2/h, 
respectively. Most of the cumulative amount–time   profiles 
shown in   Figure 2   followed a zero-order equation, except 
the W1   formulations with ALA, for which the cumulative 
amount gradually leveled off after 12 hours of application. 
The in vitro studies showed that soybean oil-containing 
O/W emulsions (W1 and W3) enhanced ALA penetration 
by 2.6-fold   compared with the corresponding control. 
Table 1  The characterization of the oil-in-water (O/W) and water-
in-oil (W/O) nanoemulsions by droplet size and zeta potential
Code Type Size (nm) Zeta potential 
(mV)
W1 O/W with soybean oil 256.3 ± 5.5 -19.9 ± 0.8
W2 O/W with squalene 238.7 ± 8.1 -25.2 ± 0.5
W3 O/W with soybean oil  
and terpineol
216.2 ± 3.7 -19.0 ± 0.6
O1 W/O with soybean oil   33.6 ± 1.6   -2.0 ± 0.4
O2 W/O with squalene 125.0 ± 2.7   -6.0 ± 0.2
O3 W/O with soybean oil  
and terpineol
  18.1 ± 0.3   0.4 ± 0.2
Note: each value represents the mean ± sD (n = 3).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Another observation was the significant inter-subject 
variation of flux values of the ALA control group. This 
variation was reduced after ALA incorporation into the nano-
emulsions. Squalene-containing O/W emulsions exhibited a 
low ALA flux of 10 nmol/cm2/h. Moreover, all O/W systems 
showed lower mALA permeation (P , 0.05) compared with 
the control vehicle. The in vitro permeation of ALA and 
mALA from W/O emulsions is depicted in Figure 3A and 
3B, respectively. Flux values are given in Table 4. The W/O 
nanocarriers turned out to be less potent in delivering drugs 
compared to the O/W systems. The drug accumulation from 
W/O emulsions was lower than that from the control solution 
at all time points, with the squalene-containing formulations 
(O2) showing the least permeation.
To clarify the mechanism of skin permeation, the release 
of ALA and mALA across cellulose membranes, through 
which the drug can freely traverse, was studied, and the 
results are shown in Table 5. The release of ALA and mALA 
from emulsions exhibited slower release compared to that 
of the aqueous solution. Release was found to be a function 
of the drug molecules, with a slower release rate for mALA. 
There was no significant difference (P . 0.05) among the 
release rates from O/W nanocarriers for either ALA or 
mALA. Preparations of drugs in W/O emulsions had much 
slower release (P , 0.05) profiles than those prepared in O/W 
emulsions. The rate of total ALA released from W/O systems 
varied from 7 to 646 nmol/cm2/h. The range of mALA release 
was from 43 to 304 nmol/cm2/h. α-Terpineol-containing W/O 
dispersions (O3) showed the highest drug release, followed 
by preparations with soybean oil as the external phase (O1) 
and those with squalene (O2).
In vivo skin permeation examined 
through cLsM
Since W1 showed an ability to enhance ALA skin perme-
ation, this formulation was selected as a model emulsion 
for further in vivo studies. Figure 4 depicts representative 
examples of CLSM images of nude mouse skin following 
in vivo topical application of ALA and mALA for 2, 4, and 
8 hours. ALA is a naturally occurring amino acid that is 
ultimately converted into PpIX within the skin. The red fluo-
rescence shown in the images was mainly derived from PpIX 
within full-thickness skin. A time-dependent increase in the 
fluorescence intensity was measured for all test formulations. 
There was no significant difference in fluorescence intensities 
between the ALA control solution and O/W emulsions at each 
time point (Figure 4A vs B). The main difference between 
the two vehicles was the greater numbers of filaments, which 
were considered to be hair follicles, in the images of W1 
application for 8 hours. The same phenomenon was observed 
with mALA application (Figure 4C vs D). For the images 
of mALA, the intensity of the red fluorescence was much 
greater from W1 than from the control at 2 hours.
The CLSM fluorescence of the accumulated PpIX 
observed after ALA or mALA application can give an indi-
cation of the spatial distribution. The skin thickness was 
further scanned at about 10-µm increments for 16 fragments 
Table 2 The droplet size of the oil-in-water (O/W) and water-in-oil (W/O) nanoemulsions in the presence of 5-aminolevulinic acid 
(ALA) or methyl (m)ALA
Code Type Without drug ALA mALA
W1 O/W with soybean oil 256.3 ± 5.5 258.6 ± 2.3 269.3 ± 5.8
W2 O/W with squalene 238.7 ± 8.1 237.6 ± 5.6 253.9 ± 5.7
W3 O/W with soybean oil and terpineol 216.2 ± 3.7 218.5 ± 1.3 231.9 ± 1.2
O1 W/O with soybean oil   33.6 ± 1.6   57.7 ± 2.0   41.1 ± 0.5
O2 W/O with squalene 125.0 ± 2.7 424.6 ± 33.5 282.1 ± 15.9
O3 W/O with soybean oil and terpineol   18.1 ± 0.3   64.7 ± 1.6   26.1 ± 3.3
Note: each value represents the mean ± sD (n = 3).
Table 3 The encapsulation efficiency (%) of 5-aminolevulinic acid 
(ALA) and methyl (m)ALA in oil-in-water (O/W) nanoemulsions
Code Type ALA mALA
W1 O/W with soybean oil 16.18 ± 1.53 67.95 ± 1.82
W2 O/W with squalene   6.66 ± 5.48 51.87 ± 3.25
W3 O/W with soybean oil  
and terpineol
11.44 ± 1.22 60.58 ± 6.50
Note: each value represents the mean ± sD (n = 3).
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Figure 1 Fluorescence emission spectra of Nile red (1 ppm) in oil-in-water (O/W) 
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starting at the surface of the skin (left to right, top to bottom). 
Figure 5 shows the separate images of the skin treated with 
test vehicles for 8 hours. Since the thicknesses of nude mouse 
stratum corneum (SC) and epidermis are ∼11 and ∼18 µm, 
respectively,15 the first four fragments can be characterized 
as the SC and epidermal layers. The red fluorescence was 
generally higher in the dermis than in the SC and epidermis 
for all formulations tested. The intensity of the fluorescence 
gradually faded away with an increase in the skin depth. 
The extent and distribution of PpIX derived from ALA in 
the emulsions did not exceed those derived from the control 
vehicle (Figure 5A vs B). Representative fluorescence stain-
ing indicated enhanced mALA penetration into deeper skin 
layers after application of the nanocarrier systems compared 
to the control (Figure 5C vs D). According to the sole image 
with red fluorescence in Figure 5C and 5D, the penetration 
depth of PpIX from mALA could be increased from 100 µm 
(control) to 140 µm (W1), which would reach the layer of 
lower dermis. The administration of mALA O/W emulsions 
extensively and homogeneously increased the fluorescence 
intensity of the skin. It can be seen that the fluorescence levels 
Time (h)
C
u
m
u
l
a
t
i
v
e
 
a
m
o
u
n
t
 
(
n
m
o
l
/
c
m
2
 
) 12000
10000
8000
6000
4000
2000
0
01 02 03 0
Control
W1
W2
W3
40
A
Time (h)
C
u
m
u
l
a
t
i
v
e
 
a
m
o
u
n
t
 
(
n
m
o
l
/
c
m
2
 
) 3000
2500
2000
1500
1000
500
0
0 10 20 30
Control
W1
W2
W3
40
B
Figure 2 In vitro cumulative amount (nmol/cm2)–time profiles of 5-aminolevulinic acid (ALA) (A) and methyl (m)ALA (B) from the aqueous control (double-distilled water) 
and oil-in-water (O/W) emulsion systems (W1 to W3) across porcine skin. each value represents the mean ± sD (n = 4).
Table 4 The in vitro flux (nmol/cm2/h) of 5-aminolevulinic acid 
(ALA) and methyl (m)ALA from oil-in-water (O/W) and water-
in-oil (W/O) nanoemulsions via porcine skin
Code ALA mALA
control   69.75 ± 55.87 42.57 ± 5.80
W1 180.24 ± 29.89 25.85 ± 8.53
W2   10.23 ± 0.83   2.83 ± 1.03
W3 176.14 ± 47.32 33.02 ± 5.09
O1   11.03 ± 3.92   5.72 ± 0.20
O2   1.36 ± 0.15   4.15 ± 2.65
O3   34.63 ± 8.82   7.91 ± 2.47
Note: each value represents the mean ± sD (n = 4).
at the depths of the first six fragments for mALA emulsions 
mainly came from hair follicles, indicating the importance 
of shunt routes.
In vivo skin irritation test
To ensure that the topical preparations are innocuous, it 
is necessary to examine possible irritation caused by the 
  emulsions. TEWL, erythema, and pH were used to evaluate 
the preliminary safety of W1 and W3 in vivo. The ∆ value 
(the value of the treated site minus the value of an adjacent 
site) was determined after 24 hours of application, as shown 
in Figure 6. No significant skin irritation was detected when 
the bar of the standard deviation (SD) passes across the zero 
line in Figure 6. We did not see an irritant response with 
these formulations, suggesting tolerance of the skin to the 
topically applied vehicles. The incorporation of α-terpineol 
(W3) induced no skin change (P . 0.05). Close inspection 
of the underlying application site also demonstrated that 
the emulsions did not induce visible skin reddening or 
disruption.
Discussion
The present work attempted to develop nanoemulsions to 
enhance the permeation of ALA and mALA via the skin. 
The effects of different oil compositions on drug delivery 
were compared. It was found that emulsions with differ-
ent matrices provided various functions for modulating 
drug permeation, with soybean oil-loaded O/W emulsions 
exhibiting the greatest enhancement. The influences of these 
nanocarriers on the delivery of ALA and its prodrug were 
also distinct from each other.
The principal components of soybean oil are glycerides 
with polyunsaturated fatty acids including oleic, linoleic, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and linolenic acids.17 Squalene is an all-trans isoprenoid 
containing 6 isoprene units, and is a naturally occurring 
  substance found in humans. There was no pronounced 
difference in the droplet size between the O/W emulsions 
composed of soybean oil (W1) and squalene (W2), although 
soybean oil produced larger droplets. A significant difference 
was observed in the W/O emulsions, with squalene (O2) 
showing 4-fold larger droplets compared to soybean oil 
(O1). This may indicate that the emulsifier system with a 
determined hydrophile–lipophile balance (HLB) used in 
W/O emulsions (Span 80 and Brij 98) could completely 
emulsify and stabilize the aqueous phase and soybean oil 
but not squalene. The addition of the permeation enhancer, 
α-terpineol, reduced the droplet size. This is because the 
  stabilization and   mixing of the two phases with these emul-
sifiers were easier in the α-terpineol-containing system,18 
resulting in the production of smaller droplet sizes.
The negative surface charge shown by O/W emulsions 
is believed to have resulted in the ionization of Myverol. 
Some free fatty acids derived from the hydrolysis of 
  monoglycerides in Myverol may have occurred, contributing 
to the negative charge at the interface. The zeta potential 
of squalene-containing formulations (W2) indicated that 
additional negative charges existed compared to soybean 
  oil-containing ones (W1). This means that more Myverol may 
have been exposed at the interface. Myverol is characterized 
as a lipophilic emulsifier. According to the results of the 
analysis of the molecular environment, the lipophilicity of 
the oil droplets was less with squalene than with soybean oil. 
Myverol molecules tended to escape the inner squalene core 
with its low lipophilicity, thus exposing themselves at the 
interface. Another reason is the similarity of the composition 
between Myverol and soybean oil (glycerides), leading to the 
inclusion of Myverol in the inner soybean oil phase. The zeta 
potential of the W/O systems was nearly zero since Span 80 
and Brij 98 are both non-ionic surfactants.
The log P (octanol/water partition coefficient) of ALA is 
negative (-1.5), as is that of the methyl ester (-0.9).19 Hence 
both ALA and mALA are basically hydrophilic. Because of 
the lipophilic matrix of O/W emulsions, hydrophilic agents 
are expected to be poorly entrapped within the inner phase. 
It is surprising that the O/W nanocarriers could entrap both 
drugs to a certain extent, especially mALA. As ALA is an 
amphoteric molecule, it probably strongly interacts with the 
emulsifier layers of the emulsions.20 This effect may have 
been more significant for mALA molecules. Another pos-
sibility is that some hydrophilic substances such as CAT-1 
and penciclovir can be easily localized within the PF68 
layer of the nanoparticles.21,22 mALA may have largely been 
embedded in the interface of the O/W emulsions, resulting in 
a certain increase in the mean droplet size over the drug-free 
dispersions. This phenomenon was not detected for ALA with 
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Figure 3 In vitro cumulative amount (nmol/cm2)–time profiles of 5-aminolevulinic acid (ALA) (A) and methyl (m)ALA (B) from the aqueous control (double-distilled water) 
and water-in-oil (W/O) emulsion systems (O1 to O3) across porcine skin. each value represents the mean ± sD (n = 4).
Table 5 The in vitro release rate (nmol/cm2/h) of 5-aminolevulinic 
acid  (ALA)  and  methyl  (m)ALA  from  oil-in-water  (O/W)  and 
water-in-oil (W/O) nanoemulsions via porcine skin
Code ALA mALA
control 1850.76 ± 40.95 390.30 ± 32.69
W1 1642.24 ± 195.00 223.55 ± 4.04
W2 1411.02 ± 41.45 226.92 ± 25.47
W3 1410.61 ± 62.34 207.83 ± 27.27
O1   16.55 ± 1.62 101.55 ± 18.38
O2     6.68 ± 1.13   43.02 ± 4.14
O3   645.79 ± 31.10 303.74 ± 70.61
Note: each value represents the mean ± sD (n = 4).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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O/W emulsions, especially W1. Another drawback for 
topical ALA delivery is the marked inter- and intra-subject 
variations that occur in human skin.25 A similar result was 
observed in the present work for the ALA-loaded aqueous 
control. With no reproducible control over ALA permeation 
to neoplastic lesions, it is inevitable that potential variations 
in therapeutic outcomes after PDT may become difficult to 
reconcile.7 The nanoemulsions attenuated the high variation 
that occurred with the ALA aqueous solution. ALA ester 
derivatives would be expected to cross cellular membranes 
more easily than ALA. That was not the case in this study, 
since mALA demonstrated lower in vitro permeation across 
the skin compared with ALA with the O/W emulsions. This 
can be attributed to the fact that ALA was mainly dissolved 
in the aqueous external phase and, hence, was immediately 
available for release. The mALA molecules were dispersed 
in the interface of the droplets and, therefore, had to partition 
into the external phase before diffusing to the skin surface 
for release.26 The encapsulation efficiency and drug release 
profiles confirm this speculation. It seems that mALA could 
overcome the concentration gradient threshold before a 
  significant permeation across the skin could be induced.
A previous study27 indicated that liposomes with lipid 
compositions similar to the SC increase ALA permeation. 
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Figure 4 confocal laser scanning microscopic (cLsM) micrographs of nude mouse 
skin after the in vivo topical administration of 5-aminolevulinic acid (ALA) for 2, 4, 
and 8 hours (left image to right image) from the aqueous control (double-distilled 
water) (A), ALA from oil-in-water (O/W) soybean oil emulsions (W1) (B), methyl 
(m)ALA from the aqueous control (double-distilled water) (C), and mALA from 
O/W soybean oil emulsions (W1) (D).
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Figure 5 confocal laser scanning microscopic (cLsM) micrographs of nude mouse 
skin after the in vivo topical administration of 5-aminolevulinic acid (ALA) via the 
skin for 8 hours from the aqueous control (double-distilled water) (A), ALA from 
oil-in-water  (O/W)  soybean  oil  emulsions  (W1)  (B),  methyl  (m)ALA  from  the 
aqueous control (double-distilled water) (C), and mALA from O/W soybean oil 
emulsions (W1) (D). The skin specimen was viewed by cLsM at ∼10-µm increments 
by a separate X, Y-sections at each Z-axis from the skin surface to the bottom as the 
arrows indicate (left to right, top to bottom).
its lower encapsulation. Soybean oil provided greater drug 
encapsulation efficiency than did squalene. Soybean oil is a 
mixture with different fatty acids, whereas squalene is a pure 
compound. Mixed lipids always form less densely packed 
structures which should favor drug incorporation.23 In the 
W/O nanocarriers, ALA-loaded formulations were composed 
of larger droplets compared with mALA-loaded formula-
tions. Since ALA demonstrated a higher water solubility than 
mALA, most of the ALA molecules may have been located 
in the aqueous core of the W/O emulsions. This may have 
increased the dimension of the aqueous phase. On the other 
hand, mALA may have largely resided in the interface. The 
increase in size was thus confined to a certain range.
It is evident that the successful topical application of 
ALA for epidermal tumors would require application times 
of at least 24–48 hours.24 The aqueous control of ALA may 
have failed to achieve this duration because of the restricted 
increase in the in vitro cumulative amount after a 12-hour 
application. This disadvantage was improved by using the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Squalene is a structurally unique compound that is one of the 
main components (about 13%) of skin surface lipids.28 Our 
results showed that squalene-containing O/W emulsions did 
not efficiently deliver ALA into the skin. This indicates the 
importance of oil components to modulate the percutaneous 
penetration of ALA and mALA. Penetration enhancers may 
alter the organization of the intercellular lipids of the SC, 
thereby facilitating the skin permeation of ALA. That was 
not the case in the present work, since α-terpineol inclusion 
in O/W systems (W3) did not further increase drug perme-
ation from soybean oil-containing emulsions (W1). This may 
have been due to the existence of α-terpineol in the inner 
phase. Thus α-terpineol could not directly interact with the 
SC lipids. Contrary to this result, a significant increase in 
the drug flux was observed with α-terpineol incorporation 
in the external phase of W/O emulsions.
Lipid nanoparticles with smaller diameters are advanta-
geous for improving the permeation of particles into the 
skin.29 Although the W/O emulsions developed in this work 
had a smaller size than the O/W carriers, the drug flux 
from W/O emulsions was relatively lower than that from 
O/W ones. This indicates that there was no influence of the 
emulsion droplet size on the skin penetration of ALA and 
its ester. The release rate was determined to govern the skin 
permeation of ALA and mALA after comparing the fluxes 
of O/W and W/O emulsions. A high ALA release rate would 
promote high skin permeation and therefore be advantageous 
for therapy.30 It can be seen that the emulsions decreased drug 
release compared with the release from the control solution. 
ALA and mALA are hydrosoluble, and thus have higher 
affinities for the aqueous phase. The O/W type formulations 
contained a certain proportion of lipids, and this may have 
hindered the release of the incorporated water-soluble drugs.7 
W/O-type formulations released ALA and mALA to a lesser 
extent than the O/W type because of the required process of 
drug partitioning from the inner phase to the external phase 
and then diffusion through external phase. Another reason 
for the low drug release of W/O emulsions was their high 
viscosity. With an increase in the oil phase of emulsions, the 
viscosity increases.31 It is possible that the high viscosity of 
the colloidal systems can play a role in lowering the overall 
release rate and subsequent skin permeation.32,33 There was a 
linear correlation between the release rate and flux of drugs 
from the three W/O formulations. Moreover, a decrease in 
the W/O droplet size led to an increase in drug permeation. 
The rate of release generally increases with smaller droplets, 
since a small-droplet system has a larger total surface area 
where drug diffusion can occur.23,34
The CLSM profiles suggested that the accumulation 
and distribution of PpIX in skin exposed to mALA were 
improved by the presence of certain O/W emulsions. 
  Increasing the application time from 2 to 4 and 8 hours 
resulted in significant increases in tissue concentrations of 
both drugs. This is   reasonable since the typical residence 
time of topically applied ALA is in the range of 4–8 hours.7 
The earliest PpIX accumulation is in the epidermis, followed 
by the eccrine and apocrine glands, then hair follicles and 
sebaceous glands.35 There was a trend for hair follicles to 
express strong fluorescence in emulsion-treated skin after 
8 hours of application. Previous studies6,36,37 indicated that 
the induction of PpIX accumulation by ALA and mALA is 
pronounced in hair   follicles and sebaceous glands. Follicles 
and sebaceous glands are localized relatively deeply in the 
skin.38 Christiansen et al2 suggested that liposome-loaded 
ALA is preferentially absorbed in hair follicles. The nano-
emulsions developed in this work likely exerted similar 
effects as liposomes.
Some in vivo studies39,40 suggested that topical application 
of ALA esters can result in greater PpIX accumulation than 
ALA. Although mALA exhibited a lower in vitro cumulative 
amount in the receptor compared to ALA, the in vivo CLSM 
results showed comparable fluorescence intensities between 
ALA and mALA. Moreover, no significant difference 
between the fluorescence intensities of ALA emulsions and 
the aqueous control was observed. This may have been due 
to the enzyme-limited metabolic process of ALA in skin.41,42 
The cutaneous PpIX accumulation becomes saturated when 
a great amount of ALA is absorbed by the skin. The ester 
TEWL
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Figure 6 In vivo skin irritation examination determined by transepidermal water 
loss (TeWL), ph value, and erythema (a*) after a 24-hour application of topically 
applied oil-in-water (O/W) soybean oil emulsion systems (W1 and W3). 
Notes: The ∆ value indicates the value of the treated site minus the value of an 
adjacent untreated site. All data are presented as the mean of 4 experiments ± sD.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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prodrug even provided a deeper PpIX distribution when 
delivered by the O/W soybean oil emulsions. For optimal effi-
cacy, PDT drugs should ideally penetrate the skin to reach the 
target   tissue at sufficiently high concentrations.   Cutaneous 
  delivery of ALA failed to produce measurable quantities 
within the skin, in particular for deeper dermal and subepi-
dermal tumors.7,24 Nodular BCC is an example of cells located 
deeper than the epidermis. The O/W emulsions containing 
soybean oil clearly promoted mALA penetration to the deeper 
skin compared with the aqueous solution. As a consequence, 
topical administration of mALA emulsions is promising for 
targeting lesions underlying the epidermis. Of course this 
does not mean that ALA in soybean oil emulsions is of no 
use to efficiently target skin lesions. Lopez et al19 suggested 
that in vitro measurement of the ALA flux into the receptor 
provides some evidence of its local cutaneous availability, 
especially in deeper tissues.
The in vitro and in vivo permeation results suggest that 
enhanced drug skin delivery was achieved by the O/W 
soybean oil emulsions. Since the release rate from the 
formulations cannot explain this high skin absorption, other 
mechanisms may predominate the delivery of nanocarriers. 
These include the role of hair follicles/sebaceous glands, the 
enhancer effect, and an increase in thermodynamic activity. 
One of the features that make lipid nanocarriers interesting for 
dermatological applications is their tendency to preferentially 
penetrate and accumulate in hair follicles.43,44 Oil droplets are 
compatible with the sebum and are preferably transported 
into follicles/sebaceous glands. The higher flexibility of 
nanocarriers may be an advantage within the narrow slot 
between the hair root sheath and shaft.45 Penetration of 
soybean oil emulsions had a more flexible character because 
of the mixture of different fatty acids. Penetration of squalene 
droplets may have been retarded because of their rigid 
structure based on the ordered arrangement of the inner-phase 
construction. The importance of hair follicles for emulsion 
penetration was verified by the in vivo CLSM results for 
mALA. However, this effect of permeation enhancement for 
mALA was not detected in the in vitro receptor compartment. 
This was because after skin excision, the follicular volume 
was reduced by the contraction of the elastic fibers so that the 
follicles were less receptive to the applied substances.46,47
The rate-limiting step for ALA and mALA uptake into 
skin lies at the level of the SC.48 Crossing the SC is essential 
for ALA conversion to PpIX in the skin. The nanoemulsions 
interacted with the lipid structure of the SC in such a way that 
facilitated the permeation of drugs across the skin. Fatty acids 
and glycerides can be used as effective penetration enhancers 
for a variety of drugs.49 Fatty acids can enter the bilayers, and 
perturb them by creating separate domains. The unsaturated 
cis configuration perturbs the lipid packing more than does 
a trans configuration.50 Monoolein is a mixture of glycerides 
and other fatty acids, mainly glycerol monooleate. It is an 
effective permeation enhancer for ALA.8,19 Some unsaturated 
fatty acids and glycerides are derived from the hydrolysis of 
soybean oil, meaning that this oil has a penetration enhancer 
role. This effect was not observed for squalene. Although 
intact lipid particles basically do not penetrate the SC, uptake 
of their components is to be expected.51 Liquid-state droplets 
perturbing the lipid organization in the deeper horny layer 
are more effective than rigid-state vesicles in increasing skin 
permeation.23
For nanocarriers, issues such as the thermodynamic 
  activity of the permeant relative to the vehicle are very impor-
tant, as they determine the push into the skin.13   Differences 
in the internal structure of the emulsions can modify the 
thermodynamic activity of ALA, which could favor its 
partitioning into the SC. O/W soybean oil emulsions may 
provide higher thermodynamic activity for ALA and mALA 
than squalene-containing carriers. A detailed investigation 
of the enhancing mechanisms of drug permeation was not 
the main effort in this study. Although the follicular pathway 
and enhancer effect succeeded in elucidating the penetration 
of ALA and mALA from the nanocarriers, the skin target-
ing mechanisms are unclear, and further investigations are 
needed in the future.
In topical formulations, the irritation issue is not 
considered in many cases. It is important to find a balance 
between skin permeation and skin irritation of a particular 
vehicle for practical use. TEWL was used to assess the degree 
of SC disruption. The a*-coordinate of colorimetry (which 
indicates erythema) was demonstrated to correlate well with 
inflammation of the skin.52 It was found that although W1 and 
W3 almost tripled the flux of ALA, no or negligible increases 
in TEWL and a* were detected. This result suggests that 
the barrier function of the skin was not compromised by the 
preparations. Contact between the skin and the formulations 
may provoke acceptable tolerance.
Conclusion
ALA and mALA were formulated at equimolar concentrations 
in O/W and W/O nanoemulsions for skin delivery. We showed 
that not only the choice of the drug, but also the emulsion 
type and the oil phase are all important considerations when 
attempting to optimize topical drug permeation. The O/W 
soybean oil dispersions were most promising because of their International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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ability to exert the highest in vitro ALA flux. The uniformity 
of drug flux by the emulsions was improved when compared to 
the aqueous control. The addition of α-terpineol, a penetration 
enhancer, as a part of the oil phase did not further increase 
drug permeation via the skin. The optimized formulations 
could also deliver mALA to deeper layers of the skin. 
The release rate of the drugs from the inner phase was the 
main mechanism governing the skin permeation from W/O 
emulsions. On the other hand, follicular routes, a penetration 
enhancer effect, and increases in thermodynamic activity were 
possible factors predominating the permeation enhancement 
of O/W soybean oil emulsions. The skin irritation test 
indicated negligible skin disruption and acceptable safety of 
the prepared nanocarriers.
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